ADIPOQ and type 2 diabetes mellitus: Our results are in accordance with previous reports [21, 46] including ours [25] that failed to associate adiponectin levels with carotid IMT in patients with T2D and suggested a loss of anti-atherogenic effect of adiponectin in T2D.